Jessica Fye
Stock Analyst at JP Morgan
(3.54)
# 988
Out of 4,412 analysts
100
Total ratings
45.16%
Success rate
5.52%
Average return
Main Sectors:
39 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Overweight | $165 → $167 | $135.90 | +22.88% | 2 | Apr 2, 2024 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $6 → $13 | $12.41 | +4.75% | 2 | Mar 26, 2024 | |
| BNTX BioNTech SE | Maintains: Underweight | $99 → $90 | $87.21 | +3.20% | 5 | Mar 22, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $170 → $190 | $109.46 | +73.58% | 2 | Mar 22, 2024 | |
| DCPH Deciphera Pharmaceuticals | Maintains: Neutral | $14 → $16 | $14.65 | +9.22% | 4 | Mar 20, 2024 | |
| IMCR Immunocore Holdings | Maintains: Overweight | $60 → $70 | $58.46 | +19.74% | 3 | Mar 20, 2024 | |
| BGNE BeiGene | Maintains: Overweight | $184 → $186 | $153.58 | +21.11% | 2 | Mar 19, 2024 | |
| NVCR NovoCure | Maintains: Neutral | $15 → $17 | $12.64 | +34.55% | 3 | Mar 19, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $438 → $450 | $397.48 | +13.21% | 4 | Feb 6, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $52 → $55 | $41.59 | +32.24% | 1 | Feb 1, 2024 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Neutral | $25 → $45 | $42.47 | +5.96% | 4 | Dec 28, 2023 | |
| MRNA Moderna | Maintains: Neutral | $93 → $90 | $107.97 | -16.64% | 5 | Dec 1, 2023 | |
| NKTR Nektar Therapeutics | Reinstates: Underweight | n/a | $1.32 | - | 3 | Nov 20, 2023 | |
| EBS Emergent BioSolutions | Reinstates: Underweight | n/a | $1.92 | - | 2 | Nov 20, 2023 | |
| ESPR Esperion Therapeutics | Reinstates: Neutral | n/a | $1.90 | - | 6 | Nov 20, 2023 | |
| AMRN Amarin Corporation | Reinstates: Underweight | n/a | $0.87 | - | 2 | Nov 20, 2023 | |
| BCRX BioCryst Pharmaceuticals | Reinstates: Overweight | $10 | $4.16 | +140.38% | 2 | Nov 20, 2023 | |
| MIRM Mirum Pharmaceuticals | Reinstates: Overweight | $37 | $24.46 | +51.27% | 2 | Nov 20, 2023 | |
| CRNX Crinetics Pharmaceuticals | Reinstates: Overweight | $35 | $42.12 | -16.90% | 2 | Nov 20, 2023 | |
| DNLI Denali Therapeutics | Reinstates: Overweight | $28 | $15.43 | +81.46% | 2 | Nov 20, 2023 | |
| INSM Insmed | Reinstates: Overweight | $36 | $24.80 | +45.16% | 1 | Nov 20, 2023 | |
| ALKS Alkermes | Reinstates: Neutral | $33 | $24.68 | +33.71% | 3 | Nov 20, 2023 | |
| ITCI Intra-Cellular Therapies | Maintains: Overweight | $58 → $62 | $73.26 | -15.37% | 3 | Jun 5, 2023 | |
| LEGN Legend Biotech | Maintains: Overweight | $65 → $76 | $45.30 | +67.77% | 2 | Apr 19, 2023 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $54 → $52 | $38.57 | +34.82% | 3 | Feb 23, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $80 | $51.68 | +54.80% | 2 | Feb 8, 2023 | |
| UTHR United Therapeutics | Maintains: Overweight | $240 → $265 | $233.85 | +13.32% | 5 | Nov 3, 2022 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $140 → $112 | $80.91 | +38.43% | 1 | Oct 24, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Neutral | $204 → $200 | $143.31 | +39.56% | 1 | Oct 24, 2022 | |
| CARA Cara Therapeutics | Upgrades: Overweight | $17 → $20 | $0.68 | +2,822.69% | 2 | Mar 8, 2022 | |
| LABP Landos Biopharma | Maintains: Neutral | $150 → $70 | $22.31 | +213.76% | 2 | Jan 3, 2022 | |
| APRE Aprea Therapeutics | Downgrades: Underweight | n/a | $5.20 | - | 1 | Aug 20, 2021 | |
| LVTX LAVA Therapeutics | Initiates: Overweight | n/a | $2.73 | - | 1 | Apr 19, 2021 | |
| LXRX Lexicon Pharmaceuticals | Upgrades: Neutral | n/a | $1.58 | - | 2 | Jan 29, 2021 | |
| MRSN Mersana Therapeutics | Downgrades: Underweight | n/a | $2.94 | - | 4 | Mar 11, 2019 | |
| NVAX Novavax | Downgrades: Underweight | n/a | $4.09 | - | 3 | Feb 28, 2019 | |
| RDUS Radius Health | Maintains: Overweight | n/a | $17.90 | - | 4 | Nov 2, 2018 | |
| CMRX Chimerix | Downgrades: Underweight | n/a | $0.90 | - | 1 | Feb 14, 2018 | |
| ENTA Enanta Pharmaceuticals | Downgrades: Neutral | n/a | $12.37 | - | 1 | Feb 8, 2018 |
Ascendis Pharma
Apr 2, 2024
Maintains: Overweight
Price Target: $165 → $167
Current: $135.90
Upside: +22.88%
Stoke Therapeutics
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $12.41
Upside: +4.75%
BioNTech SE
Mar 22, 2024
Maintains: Underweight
Price Target: $99 → $90
Current: $87.21
Upside: +3.20%
Jazz Pharmaceuticals
Mar 22, 2024
Maintains: Overweight
Price Target: $170 → $190
Current: $109.46
Upside: +73.58%
Deciphera Pharmaceuticals
Mar 20, 2024
Maintains: Neutral
Price Target: $14 → $16
Current: $14.65
Upside: +9.22%
Immunocore Holdings
Mar 20, 2024
Maintains: Overweight
Price Target: $60 → $70
Current: $58.46
Upside: +19.74%
BeiGene
Mar 19, 2024
Maintains: Overweight
Price Target: $184 → $186
Current: $153.58
Upside: +21.11%
NovoCure
Mar 19, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $12.64
Upside: +34.55%
Vertex Pharmaceuticals
Feb 6, 2024
Maintains: Overweight
Price Target: $438 → $450
Current: $397.48
Upside: +13.21%
Ionis Pharmaceuticals
Feb 1, 2024
Maintains: Neutral
Price Target: $52 → $55
Current: $41.59
Upside: +32.24%
Cerevel Therapeutics Holdings
Dec 28, 2023
Maintains: Neutral
Price Target: $25 → $45
Current: $42.47
Upside: +5.96%
Moderna
Dec 1, 2023
Maintains: Neutral
Price Target: $93 → $90
Current: $107.97
Upside: -16.64%
Nektar Therapeutics
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $1.32
Upside: -
Emergent BioSolutions
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $1.92
Upside: -
Esperion Therapeutics
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $1.90
Upside: -
Amarin Corporation
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.87
Upside: -
BioCryst Pharmaceuticals
Nov 20, 2023
Reinstates: Overweight
Price Target: $10
Current: $4.16
Upside: +140.38%
Mirum Pharmaceuticals
Nov 20, 2023
Reinstates: Overweight
Price Target: $37
Current: $24.46
Upside: +51.27%
Crinetics Pharmaceuticals
Nov 20, 2023
Reinstates: Overweight
Price Target: $35
Current: $42.12
Upside: -16.90%
Denali Therapeutics
Nov 20, 2023
Reinstates: Overweight
Price Target: $28
Current: $15.43
Upside: +81.46%
Insmed
Nov 20, 2023
Reinstates: Overweight
Price Target: $36
Current: $24.80
Upside: +45.16%
Alkermes
Nov 20, 2023
Reinstates: Neutral
Price Target: $33
Current: $24.68
Upside: +33.71%
Intra-Cellular Therapies
Jun 5, 2023
Maintains: Overweight
Price Target: $58 → $62
Current: $73.26
Upside: -15.37%
Legend Biotech
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $45.30
Upside: +67.77%
Halozyme Therapeutics
Feb 23, 2023
Maintains: Overweight
Price Target: $54 → $52
Current: $38.57
Upside: +34.82%
Incyte
Feb 8, 2023
Maintains: Neutral
Price Target: $82 → $80
Current: $51.68
Upside: +54.80%
United Therapeutics
Nov 3, 2022
Maintains: Overweight
Price Target: $240 → $265
Current: $233.85
Upside: +13.32%
BioMarin Pharmaceutical
Oct 24, 2022
Maintains: Overweight
Price Target: $140 → $112
Current: $80.91
Upside: +38.43%
Alnylam Pharmaceuticals
Oct 24, 2022
Maintains: Neutral
Price Target: $204 → $200
Current: $143.31
Upside: +39.56%
Cara Therapeutics
Mar 8, 2022
Upgrades: Overweight
Price Target: $17 → $20
Current: $0.68
Upside: +2,822.69%
Landos Biopharma
Jan 3, 2022
Maintains: Neutral
Price Target: $150 → $70
Current: $22.31
Upside: +213.76%
Aprea Therapeutics
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $5.20
Upside: -
LAVA Therapeutics
Apr 19, 2021
Initiates: Overweight
Price Target: n/a
Current: $2.73
Upside: -
Lexicon Pharmaceuticals
Jan 29, 2021
Upgrades: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Mersana Therapeutics
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $2.94
Upside: -
Novavax
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $4.09
Upside: -
Radius Health
Nov 2, 2018
Maintains: Overweight
Price Target: n/a
Current: $17.90
Upside: -
Chimerix
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $0.90
Upside: -
Enanta Pharmaceuticals
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $12.37
Upside: -